evelo
biosciences
host
key
opinion
leader
discussion
focused
unmet
need
psoriasis
atopic
dermatitis
potential
opportunity
cambridge
globe
newswire
evelo
biosciences
nasdaq
evlo
clinical
stage
biotechnology
company
developing
new
modality
orally
delivered
systemically
acting
biologics
today
announced
host
key
opinion
leader
discussion
unmet
need
psoriasis
atopic
dermatitis
including
potential
serve
new
therapeutic
option
patients
living
mild
moderate
disease
event
held
virtually
thursday
october
et
part
event
benjamin
ehst
dermatologist
investigator
clinical
associate
professor
oregon
medical
research
center
discuss
current
treatment
landscape
unmet
need
psoriasis
additionally
evelo
management
host
panel
discussion
ehst
review
opportunity
atopic
dermatitis
evelo
management
team
also
review
design
recently
initiated
phase
trial
psoriasis
provide
overview
clinical
data
generated
date
well
company
platform
upcoming
milestones
access
live
event
please
dial
domestic
international
refer
conference
id
live
webcast
event
also
available
news
events
investors
section
evelo
website
http
archived
webcast
available
evelo
website
approximately
two
hours
completion
event
available
days
following
call
benjamin
ehst
benjamin
ehst
dermatologist
clinical
associate
professor
oregon
medical
research
center
ehst
spent
early
career
oregon
health
science
university
ohsu
associate
professor
department
dermatology
honed
specialty
psoriasis
member
center
excellence
psoriasis
psoriatic
arthritis
eventually
taking
multidisciplinary
center
additionally
ehst
organized
specialty
clinic
caring
issues
individuals
alongside
patient
care
teaching
ehst
began
work
clinical
research
ohsu
acting
lead
investigator
studies
treatments
skin
diseases
atopic
dermatitis
psoriasis
granuloma
annulare
actinic
keratosis
melanoma
ehst
earned
undergraduate
degree
university
chicago
medical
doctoral
degrees
university
minnesota
combined
medical
scientist
training
program
received
residency
training
dermatology
johns
hopkins
hospital
baltimore
solidified
interest
medical
practice
clinical
research
studying
immune
response
malaria
hopkins
bloomberg
school
public
health
evelo
biosciences
evelo
biosciences
clinical
stage
biotechnology
company
developing
oral
biologics
act
small
intestinal
axis
systemic
therapeutic
effects
sintax
plays
central
role
governing
immune
metabolic
neurological
systems
company
first
product
candidates
pharmaceutical
preparations
single
strains
microbes
selected
defined
pharmacological
properties
evelo
therapies
potential
effective
safe
affordable
medicines
improve
lives
people
inflammatory
diseases
cancer
evelo
currently
four
product
candidates
development
treatment
inflammatory
diseases
including
psoriasis
atopic
dermatitis
treatment
cancer
evelo
advancing
additional
product
candidates
disease
areas
information
please
visit
engage
evelo
linkedin
